Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;10(1):177-185.
doi: 10.1002/epi4.13093. Epub 2024 Nov 9.

Epilepsy care pathway: The Finnish model

Affiliations

Epilepsy care pathway: The Finnish model

Reetta Kälviäinen et al. Epilepsia Open. 2025 Feb.

Abstract

Objective: Integrated care pathways are essential for consistent, effective epilepsy care, offering equal access and quality regardless of socioeconomic status. They must align with the WHO Global Action Plan on Epilepsy, ensuring best practices and cost-effective management. We describe the Finnish national epilepsy care pathway, which includes multiple levels of care, from initial diagnosis to long-term care for all types of epilepsy, with a specific focus on rare and complex cases integrated with the European Reference Network (ERN) for Rare and Complex Epilepsies EpiCARE.

Methods: In 2017, the Finnish government nominated Kuopio University Hospital to coordinate diagnostics and care for severe epilepsy in Finland. A national multidisciplinary consensus panel, including specialists from both adult and pediatric neurology departments across all five Finnish university hospitals and from the patient organization, was established. The resulting pathway was adopted into the current Finnish evidence-based current care guidelines for epilepsy.

Results: The Finnish epilepsy care pathway focuses on timely referrals, continuity of care and enhanced communication between healthcare providers at different levels of care. Patient involvement is assured with an individualized digital application offering secure online messaging, a seizure calendar, and remote visits. The pathway enhances virtual consultations and includes regular national diagnostic multidisciplinary meetings for severe epilepsies before selected cases are consulted in ERN EpiCARE meetings.

Significance: This Finnish model for epilepsy care provides a streamlined, multidisciplinary approach to diagnosis and treatment and combines modern digital tools, data sharing, and peer support. This pathway can serve to model how integrated healthcare systems can effectively manage complex conditions.

Plain language summary: We describe the Finnish national epilepsy care pathway, which includes multiple levels of care, from initial diagnosis to long-term care for all types of epilepsy, with a specific focus on rare and complex cases integrated with the European Reference Network (ERN) for Rare and Complex Epilepsies EpiCARE. Finnish model for epilepsy care provides a streamlined, multidisciplinary approach to diagnosis and long-term treatment of epilepsy. The pathway enhances virtual consultations and includes national and European-level diagnostic multidisciplinary meetings for severe epilepsies. To improve outcomes, we emphasize the use of modern digital tools, data sharing, and peer support.

Keywords: care continuum; care model; epilepsy management; healthcare services; integrated care pathway; rare and complex epilepsy.

PubMed Disclaimer

Conflict of interest statement

Reetta Kälviäinen: Grants from the Academy of Finland, Jane and Aatos Erkko Foundation, Saastamoinen Foundation, and Vaajasalo Foundation; honoraria from Eisai, Omamedical, Orion, Sandoz, Sanofi, and UCB; and honoraria for membership on the advisory boards of and consultation from Angelini Pharma, Eisai, Marinus Pharmaceuticals, Orion and UCB. Zakarya Hadj‐Allal: Honoraria from the U.S. Department of State, the UN's International Organization for Migration, the Association for Medical Education in Europe, ReInnovate Group, Orbital Learning Canada, and Medi Connection Oy, a grant from the Finnish National Agency for Education (EDUFI), Finland. Jarkko Kirjavainen: Travel support and expert fees from Biogen and Roche. Reina Roivainen: Personal fees from Angelini, Eisai, and Jazz Pharmaceuticals. Jukka Peltola: Clinical trials grants for Eisai, UCB, and Bial; research grants from Angelini Pharma, Eisai, Jazz Phara, Medtronic, UCB, and LivaNova; speaker's honoraria from LivaNova, Angelini Pharma, Eisai, Jazz Pharma, Medtronic, Orion Pharma and UCB; travel support from LivaNova, Eisai, Medtronic, and UCB; and on the advisory boards of LivaNova, Angelini Pharma, Jazz Pharma, Eisai, Medtronic, and UCB. Salla Lamusuo: Personal fees from Finnish Epilepsy Association, Eisai, Orion Pharma, and UCB. Tuire Lähdesmäki: Personal fees from Orion Pharma, Eisai, UCB, and Jazz Pharmaceuticals; research grants from the Finnish Government Research Funding, Finnish Pediatric Research Foundation, and Päivikki and Sakari Sohlberg Foundation. Johanna Annunen: Personal fees from Abbvie, Allergan, Angelini Pharma, Boston Scientific, Eisai, Genzyme, Jazz Pharmaceuticals, Orion Pharma, Roche, Sanofi and TEVA and has been involved in expert groups or lecturing for Allergan, Boston Scientific, Orion Pharma, Roche, Sanofi and TEVA. Päivi Vieira: Received personal fees from Eisai, Pfizer, Roche, and UCB. Virpi Tarkiainen: Grants for the FEA from Angelini Pharma, Jazz Pharmaceuticals, Nutricia Medical, OmaMedical, Orion Pharma, and UCB. Leena Jutila: Personal fees from Angelini Pharma, Eisai, UCB, and Novartis. Anni Saarela: Personal fees from UCB, Eisai, Pfizer, and Angelini Pharma, along with a grant from the Arvo and Lea Ylppö foundation. Leena Kämppi: Honoraria from UCB, Merck, and Eisai, travel support from UCB and Angelini Pharma, and research grants from the Finnish Cultural Foundation, Michael Foundation, Finnish Neurology Association, Academy of Finland, and HUS Neurocenter. Liisa Metsähonkala: Personal grants from Angelini Pharma, Takeda, Novartis, UCB, Eisai, Jazz Pharmaceuticals, Orion, and Marinus Pharmaceuticals and serves as the chair of the board of the FEA. Niina Lähde: Trial for UCB and honoraria from LivaNova (OmaMedical). Anna‐Leena Pirttisalo: Personal fees from Angelini Pharma. Laura Kela: Personal fees from TEVA. Jonna Komulainen‐Ebrahim: Personal fees from Jazz Pharmaceuticals. Paula Sorjonen: Grants for the FEA from Angelini Pharma, Jazz Pharmaceuticals, Nutricia Medical, OmaMedical, Orion Pharma, and UCB. Jarkko Kirjavainen: Travel support and expert fees from Biogen and Roche. Jukka Peltola: Clinical trials for Biohaven, Eisai, UCB, and Bial; research grants from Angelini Pharma, Eisai, Jazz Pharmaceuticals, Medtronic, UCB, and LivaNova; speaker's honoraria from LivaNova, Angelini Pharma, Eisai, Jazz Pharmaceuticals, Medtronic, Orion Pharma, and UCB; travel support from LivaNova, Eisai, Medtronic, and UCB; and on the advisory boards of LivaNova, Angelini Pharma, Jazz Pharmaceuticals, Eisai, Medtronic, and UCB. The following authors declare no conflicts of interest: Tarja Linnankivi, Kai Eriksson, Eija Gaily, Jaana Antinmaa, Sini Erme, Jari Virolainen, and Milla Ylijoki. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that thisreport is consistent with those guidelines.

Figures

FIGURE 1
FIGURE 1
The diagram illustrates the multitiered structure of the Epilepsy Care Pathway, which consists of five levels of healthcare delivery. Level 1 is the Primary Healthcare, where initial patient identification and referral to specialist care occur. Level 2 represents Specialist Care facilities for diagnosis, treatment, follow‐up, and rehabilitation. Levels 3 and 4 are Specialist Centers and Specialized Epilepsy Centers, respectively, responsible for severe epilepsy diagnostics and care within a national network. The highest tier, Level 5, is the Europe‐wide EPICARE Case Discussion platform, facilitating cross‐border consultation and collaboration on complex cases within the European Reference Networks. Arrows indicate the referral pathways and the continuum of care across different levels, highlighting the system's integrated and patient‐centred approach.

Similar articles

References

    1. Allen D, Gillen E, Rixson L. The effectiveness of integrated care pathways for adults and children in health care settings: a systematic review. JBI Libr Syst Rev. 2009;7(3):80–129. - PubMed
    1. World Health Organization . Intersectional Global Action Plan on Epilepsy and Other Neurological Disorders 2022–2031. [cited 2024 Aug 4]. Available from: https://www.who.int/publications/i/item/9789240076624
    1. The European Reference Network for Rare and Complex Epilepsies: EpiCARE. [cited 2024 Aug 4]. Available at: https://epi‐care.eu/
    1. Specialised health care in Finland. [cited 2024 Aug 4]. Available at: https://stm.fi/en/hospitals‐and‐specialised‐medical‐care
    1. Taylor B, South J, Robertson S, Ryan T, Wood E, King RL, et al. Addressing current challenges in adult nursing: describing a virtual consensus development project methodology. Nurs Open. 2022;9(2):900–907. - PMC - PubMed